Módulo 4 – Curso pós-graduado – VIH e Envelhecimento

Renal Disease in HIV Infected and HIV/HCV Co-infected patients

Gestão clínica da doença renal em doentes infetados por VIH

Bibliografia

  1. Overton E, Nurutdinova D, Freeman J, Seyfried W, Mondy Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med 2009; 10: 343-50.
  2. Mocroft A, Kirk O, Gatell J, et Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21: 1119-27.
  3. Ganesan A, Krantz E, Huppler HK, et al. Infectious Disease Clinical Research Program HIV/STI Working Group. Determinants of incident chronic kidney dis- ease and progression in a cohort of HIV-infected persons with unrestricted ac- cess to health care. HIV Med 2013; 14: 65–76.
  4. Morlat P, Vivot A, Vandenhende M-A, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004–2012. PLoS One 2013, 8:
  5. Masiá M, Padilla S, Álvarez D, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiret- roviral therapy. AIDS 2013; 27: 181-9.
  6. Wyatt CM, Winston JA, Malvestutto CD, et Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007; 21: 2101-3.
  7. D’Agati V, Appel GB. Renal pathology of human immunodeficiency virus infec- Semin Nephrol 1998; 18: 406-21.
  8. Lescure F-X, Flateau C, Pacanowski J, et al. HIV-associated kidney glomeru- lar diseases: changes with time and Nephrol Dial Transplant 2011; 27: 2349-55.
  9. Izzedine H, Hulot JS, Villard E, et Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-91.
  10. Goicoechea M, Liu S, Best B, et Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse -transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-8.
  11. Ryom L, Mocroft A, Kirk O, et al. On behalf of the D:A:D Study Group, Association between antiretroviral exposure and renal impairment among HIV- Positive persons with normal baseline renal function: the D:A:D Study. J Infect Dis 2013; 207: 1359-69.
  12. de Lastours V, Ferrari RSE, Daudon M, et High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 2013; 68: 1850-6.
  13. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney tox- icity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80.
  14. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et Tenofovir nephrotoxicity: 2011 Update, AIDS Res Treat 2011; 354908.
  15. Kirk CTM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s adverse event reporting system. AIDS 2007; 21: 1215-8.
  16. Izzedine H, M’rad MB, Bardier A, et Atazanavir crystal nephropathy. AIDS 2007; 21: 2357-8.
  17. Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 2007; 45: e105-8.
  18. Cabry F, Izzedine H, Daudon M, et al. Crystalluria and urolithiasis frequency in patients treated with antiretroviral regimen containing 11th European AIDS Conference (EACS) 2007; October 24-27, 2007; Madrid, Spain. Poster 9.1/06.
  19. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One 2013; 8:
  20. Mocroft A, Kirk O, Reiss P, et Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-78.
  21. Izzedine H, Harris M, Perazella The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5: 563-73.
  22. Del Palacio M, Romero S, Casado Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev 2012; 14: 179-87.
  23. Kalayjian RC, Bryan L, Mechekano RN, et Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26: 1907-15.
  24. Zolopa A, Ortiz R, Sax P, et al. Comparative Study of tenofovir alafenamide versus tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtric- itabine, for HIV treatment. CROI 2013. March 3-6, 2013. Atlanta, US. Abstract
  25. Sax EP, Saag MS, Yin MT, et al. Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate. CROI 2015. February 23-26, Seattle, Washington. Abstract 143LB.
  26. Cihlar T, Ray AS, Laflamme G, et al. Short communication. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV pro- tease inhibitors. Antivir Ther 2007; 12: 267-72.
  27. Tong L, Phan TK, Robison KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51: 3498-504.
  28. Stray KM, Rujuta AB, Birkus G, et Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013; 57: 4982-9.
  29. Gallant J, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1–infected patients: week 48 XIX International AIDS Conference 2012; July 22-27; 2012 Washington DC, Abs TUAB0103.
  30. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal J Acquir Immune Defic Syndr 2012; 61: 32-40.
  31. Lepist E-I, Ray Renal drug–drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 2012; 8: 433-48.
  32. Gupta SK, Eustace JA, Winston JA, et Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-85.
  33. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/ lvguidelines/adultandadolescentgl.pdf (visitado a 2017-07-17).
  34. European AIDS Clinical Society. Guidelines: Clinical management of treatment of HIV infected adults in Europe. Version 8.0 October 2015. http://www.eacsociorg/files/guidelines_8_0-english_web.pdf (visitado a 2017-07-17).
  35. Choi AI, Vittinghoff E, Deeks SG, et Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25: 1289-98.
  36. Raffi F, Babiker AG, Richert L, et al. for the NEAT001/ANRS143 Study Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96-week results from the NEAT001/ANRS143 randomised non-inferiority trial. The Lancet 2014; 384: 1942-51.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018